Pradaxa Lawsuits Mount, as Bernstein Liebhard LLP Notes FDA Approval of New Indication for Allegedly Dangerous Blood Thinner

Share Article

The Firm is evaluating Pradaxa lawsuits on behalf of individuals who allegedly suffered dangerous episodes of internal bleeding due to Pradaxa.

Free Case Review
Thousands of Pradaxa lawsuits are currently pending that allege the drug caused dangerous episodes of internal bleeding.

As thousands of Pradaxa lawsuits ( continue to move forward in federal court, Bernstein Liebhard LLP notes that the U.S. Food & Drug Administration (FDA) has approved a new indication for the blood thinner. According to an April 7th announcement from Boehringer Ingelheim Pharmaceuticals, Inc., Pradaxa is now indicated to treat venous thromboembolism, including both deep venous thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE in patients who have been previously treated.*

“Thousands of Pradaxa lawsuits are currently pending that allege the drug caused dangerous episodes of internal bleeding. Patients considering using Pradaxa should be informed of its potential side effects, especially the fact that there exists no readily available antidote to reverse internal bleeding that may accompany its use,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free and confidential case evaluations to individuals who allegedly experienced cerebral hemorrhage, gastrointestinal bleeding, or other episodes of serious internal bleeding due to Pradaxa.

Pradaxa Bleeding Litigation
Court documents indicate that nearly 2,500 Pradaxa lawsuits have been filed in a consolidated litigation underway in U.S. District Court, Southern District of Illinois on behalf of alleged victims of Pradaxa bleeding side effects. While the lawsuits acknowledge that internal bleeding is recognized as a potential side effect of Pradaxa, the complaints allege that Boehringer Ingelheim failed to provide warnings regarding the lack of a reversal agent for this potentially deadly complication. They further allege that the company wrongly touted Pradaxa as an improvement to warfarin, a blood thinner that has been used for decades.

Pradaxa was brought to market in 2010, and was initially approved to decrease the risk of strokes in people who suffer from atrial fibrillation. In February, a report aired by 7 Action News in Detroit asserted that Pradaxa may be the most complained about drug in the U.S. According to the broadcast, the FDA has received reports of 12,494 injuries and 1,158 deaths among Pradaxa users since the blood thinner was launched in the U.S. Many of these cases detailed episodes of uncontrollable internal bleeding. **

Alleged victims of Pradaxa bleeding complications may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. Find out more about Pradaxa lawsuits at Bernstein Liebhard LLP’s website. Please call 800-511-5092 to schedule a free, no obligation case review.

*, Boehringer Ingelheim, April 7, 2014
**, 7 Action News, February 25, 2014

Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website